Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab

References

• Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2163–69. doi:10.1016/S0140-6736(12)61729-2.
   PubMed Web of Science ®Google Scholar
• Leynaert B, Sunyer J, Garcia-Esteban R, Svanes C, Jarvis D, Cerveri I, Dratva J, Gislason T, Heinrich J, Janson C, et al. Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort. Thorax. 2012;67:625–31. doi:10.1136/thoraxjnl-2011-201249.
   PubMed Web of Science ®Google Scholar
• Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WOCM, et al. GABRIEL Consortium. A large-scale, consortium-based genome-wide association study of asthma. N Engl J Med. 2010;363:1211–21. doi:10.1056/NEJMoa0906312.
   PubMed Web of Science ®Google Scholar
• Portelli MA, Hodge E, Sayers I. Genetic risk factors for the development of allergic disease identified by genome-wide association. Clin Exp Allergy. 2015;45:21–23. doi:10.1111/cea.12327.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, Koth LL, Arron JR, Fahy JV. T-helper type 2-driven inflammation defines major sub-phenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–95. doi:10.1164/rccm.200903-0392OC.
   PubMed Web of Science ®Google Scholar
• Del Giacco SR, Bakirtas A, Bel E, Custovic A, Diamant Z, Hamelmann E, Heffler E, Kalayci Ö, Saglani S, Sergejeva S, et al. Allergy in severe asthma. Allergy. 2017;72:207–20. doi:10.1111/all.13072.
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Eng J Med. 2002;346:1699–705. doi:10.1056/NEJMoa012705.
   PubMed Web of Science ®Google Scholar
• Global Strategy for Asthma Management and Prevention (2019 update. accessed September 2019 www.ginasthma.org
   Google Scholar
• Xolair® (omalizumab) Prescribing Information. 2019. http://www.gene.com/download/pdf/xolair_prescribing.pdf
   Google Scholar
• Lin H, Boesel KM, Griffith DT, Prussin C, Foster B, Romero FA, Townley R, Casale TB. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol. 2004;113:297–302. doi:10.1016/j.jaci.2003.11.044.
   PubMed Web of Science ®Google Scholar
• Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol. 2004;114:527–30. doi:10.1016/j.jaci.2004.06.032.
   PubMed Web of Science ®Google Scholar
• Bhushan A, Covey LR. CD40:CD40L interactions in X‐linked and non‐X‐linked hyper‐IgM syndromes. Immunol Res. 2001;24:311–24. doi:10.1385/IR:24:3:311.
   PubMed Web of Science ®Google Scholar
• Hanf G, Brachmann I, Kleine‐Tebbe, Seybold J, Kunkel G, Suttorp N, Noga O. Omalizumab decreased IgE‐release and induced changes in cellular immunity in patients with allergic asthma. Allergy. 2006;61:1141–44. doi:10.1111/j.1398-9995.2006.01180.x.
   PubMed Web of Science ®Google Scholar
• Maggi L, Rossettini B, Montaini G, Matucci A, Vultaggio A, Mazzoni A, Palterer B, Parronchi P, Maggi E, Liotta F, et al. Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from FcεRI. Eur J Immunol. 2018 Dec;48(12):2005–14. doi:10.1002/eji.201847668.
   PubMed Web of Science ®Google Scholar
• Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559.
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–90. doi:10.1067/mai.2001.117880.
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–82. doi:10.7326/0003-4819-154-9-201105030-00002.
   PubMed Web of Science ®Google Scholar
• Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Chen H, Carrigan G, Wang Y, Veith J, Andrews EB. The xolair pregnancy registry (EXPECT): the safety of omalizumab use during pregnancy. J Allergy Clin Immunol. 2015;135(2):407–12. doi:10.1016/j.jaci.2014.08.025.
   PubMed Web of Science ®Google Scholar
• Fala L. Nucala (mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits. 2016;9:106–10.
   PubMedGoogle Scholar
• Nucala (mepolizumab) for injection, for subcutaneous use. 2015. Accessed: August 4, 2019.
   Google Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, RP M, Bradding P, RH G, AJ W, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973‐984. doi:10.1056/NEJMoa0808991.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multi-centre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–59. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Sanderson CJ. Interleukin-5, Eosinophils, and Disease. Blood. 1992;79(12):3101–09. doi:10.1182/blood.V79.12.3101.bloodjournal79123101.
   PubMed Web of Science ®Google Scholar
• Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from bench side to clinical practice. Can Respir J. 2010;17(4):e85–93. doi:10.1155/2010/318029.
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi:10.1164/rccm.200208-789OC.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4:549–56. doi:10.1016/S2213-2600(16)30031-5.
   PubMed Web of Science ®Google Scholar
• McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med. 2017;4:93. doi:10.3389/fmed.2017.00093.
   PubMed Web of Science ®Google Scholar
• Keating GM. Mepolizumab: first global approval. Drugs. 2015 Dec;75(18):2163–69. doi:10.1007/s40265-015-0513-8.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Eng J Med. 2014;371:1198–207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators SIRIUS. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, Yancey SW, Ortega HG. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. 2016;38:2058–2070.e1. doi:10.1016/j.clinthera.2016.07.010.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuvelkar R, Murgolo NJ, Taremi SS, Chou CC, Wang P, Billah MM, Egan RW. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999;11:1935–44. doi:10.1093/intimm/11.12.1935.
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of reslizumab (0.3 or 3.0 mg/kg) as treatment for patients (12-75 Years of Age) with eosinophilic asthma. 2016. Accessed August 4, 2019: http://clinicaltrials.gov/ct2/show/NCT01270464.
   Google Scholar
• Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. doi:10.1016/S2213-2600(15)00042-9.
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P. Res-5-0010 study group. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–32. doi:10.1164/rccm.201103-0396OC.
   PubMed Web of Science ®Google Scholar
• Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98. doi:10.1016/j.chest.2016.03.032.
   PubMed Web of Science ®Google Scholar
• Corren J, Weinstein S, Janka L, Zangrilli J, Phase GM. 3 Study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016 Oct;150(4):799–810. doi:10.1016/j.chest.2016.03.018.
   PubMed Web of Science ®Google Scholar
• Liu W, Ma X, Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma. A meta-analysis. Medicine (Baltimore). 2019;98(22):e15868. doi:10.1097/MD.0000000000015868.
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall’acqua WW, Stephens GL, et al. Medi-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(1):1344–53. doi:10.1016/j.jaci.2010.04.004.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–27. doi:10.1016/S0140-6736(16)31324-1.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. 2016;388:2128–41. doi:10.1016/S0140-6736(16)31322-8.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleeker E, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M. BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59. doi:10.1016/S2213-2600(18)30406-5.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M. ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–58. doi:10.1056/NEJMoa1703501.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118:3546–56.
   PubMed Web of Science ®Google Scholar
• Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–20. doi:10.1007/s11882-013-0373-9.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368:2455–66. doi:10.1056/NEJMoa1304048.
   PubMed Web of Science ®Google Scholar
• Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, Pirozzi G, Sutherland ER, Evans RR, Joish VN, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388:31–44. doi:10.1016/S0140-6736(16)30307-5.
   PubMed Web of Science ®Google Scholar
• Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280:41–56. doi:10.1111/imr.12577.
   PubMed Web of Science ®Google Scholar
• Varricchi G, Pecoraro A, Marone G, Criscuolo G, Spadaro G, Genovese A, Marone G. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front Immunol. 2018;9:1595. doi:10.3389/fimmu.2018.01595.
   PubMed Web of Science ®Google Scholar
• De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Braga M, Di Carlo V, Doglioni C, Protti MP, Recalde H. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469–78. doi:10.1084/jem.20101876.
   PubMed Web of Science ®Google Scholar
• Omori M, Ziegler S. Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin. J Immunol. 2007;178:1396–404. doi:10.4049/jimmunol.178.3.1396.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study to evaluate tezepelumab in adults & adolescents with severe uncontrolled asthma (NAVIGATOR); 2017. Accessed 14 January 2020. https://clinicaltrials.gov/ct2/show/study/NCT03347279
   Google Scholar
• Eyerich S, Metz M, Bossios A, Eyerich K. New biological treatments for asthma and skin allergies. Allergy. 2019. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Gyles SL, Xue L, Townsend ER, Wettey F, Pettipher R. A dominant role for chemoattractant receptor-homologous molecule expressed on T helper type 2 (Th2) cells (CRTH2) in mediating chemotaxis of CRTH2+ CD4+ Th2 cells in response to mast cell supernatants. Immunology. 2006;119:362–68. doi:10.1111/j.1365-2567.2006.02440.x.
   PubMed Web of Science ®Google Scholar
• Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, Pettipher R. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175:6531–36. doi:10.4049/jimmunol.175.10.6531.
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Provoost S, Maes T. Prostaglandin D2 receptor antagonism: a novel therapeutic option for eosinophilic asthma? Lancet Respir Med. 2016;4:676–77. doi:10.1016/S2213-2600(16)30201-6.
   PubMed Web of Science ®Google Scholar
• Kao CC, Parulekar AD. Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date J. Asthma Allergy. 2019;12:1–5. doi:10.2147/JAA.S167973.
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–61. doi:10.1126/science.282.5397.2258.
   PubMed Web of Science ®Google Scholar
• Firszt R, Francisco D, Church TD, Thomas JM, Ingram JL, Kraft M. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-β1 in airway fibroblasts in asthma. Eur Respir J. 2014;43:464–73. doi:10.1183/09031936.00068712.
   PubMed Web of Science ®Google Scholar
• Noonan M, Korenblat P, Mosesova S, Scheerens H, Arron JR, Zheng Y, Putnam WS, Parsey MV, Bohen SP, Matthews JG. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132:567–74. doi:10.1016/j.jaci.2013.03.051.
   PubMed Web of Science ®Google Scholar
• Panettieri R, Sjöbring U, Péterffy AM, Wessman P, Bowen K, Piper E, Colice G, Brightling CE. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511–25. doi:10.1016/S2213-2600(18)30184-X.
   PubMed Web of Science ®Google Scholar